Your browser doesn't support javascript.
loading
Are Serotonin Alterations the Link between Thrombocytopenia and Poor Immune Status among HIV Infected Individuals?
Míguez-Burbano, María José; Rodriguez, Allan; Vargas, Mayra; Tantalean, Gabriella; Valiathan, Ranjini; Chan, Wenyaw.
Afiliação
  • Míguez-Burbano MJ; School of Integrated Science and Humanity, Florida International University, Miami, FL, USA.
  • Rodriguez A; Department of Medicine, University of Miami School of Medicine, Miami, FL, USA.
  • Vargas M; School of Integrated Science and Humanity, Florida International University, Miami, FL, USA.
  • Tantalean G; School of Integrated Science and Humanity, Florida International University, Miami, FL, USA.
  • Valiathan R; Department of Psychiatry & Behavioral Sciences, University of Miami School of Medicine, Miami, FL, USA.
  • Chan W; Division of Biostatistics, School of Public Health, University of Texas-Health Science Center at Houston, USA.
J AIDS Clin Res ; 2(2)2014 Feb 10.
Article em En | MEDLINE | ID: mdl-26491607
ABSTRACT

OBJECTIVE:

Thrombocytopenia (TCP<150 × 103 cells/mm3) has emerged as a relevant factor in the clinical course of HIV. However, the mechanisms mediating such observations have not been well characterized, limiting the possibility of creating targeted interventions. Notably, platelets are the storage and transporter system for serotonin and Brain derived neurotrophic factor (BDNF), which recent laboratory studies associated with viral replication and lymphocyte survival. Thus, we posit that (1) TCP will be associated with reduced levels of BDNF and serotonin (2) That these alterations will lead to poor viro-immune responses to antiretroviral therapy.

METHODS:

To achieve this goal, a total of 400 people living with HIV were consecutively enrolled to characterize the frequency of thrombocytopenia in hazardous and non-hazardous alcohol user populations in the HAART era. Then, participants underwent immune and laboratory assessments, to determine if TCP was associated with alterations in serotonin (5-HT) and brain derived neurotrophic factor (BDNF).

RESULTS:

The prevalence of thrombocytopenia in this antiretroviral treated cohort was 14%. Rates were significantly higher in the heavy alcohol users, HAU versus the non HAU group (Heavy 25% versus HAU 15% versusnon-HAU 10%). Multivariate model analyses indicated that having TCP, low BDNF levels (<5000 pg/ml), and number of drinks per day were predictors of serotonin levels. PLWH with TCP had about 2-fold lower PPP-BDNFlevels (5037.4 ± 381 vs. 9137.5 ± 7062 pg/ml p=0.0001). Other significant predictors of BDNF levels at the last visit included receiving selective serotonin reuptake inhibitors and PPP serotonin levels. Multivariate analyses also confirmed that altered serotonin levels were associated withhigh viral loadsboth low CD4 cell counts.

CONCLUSIONS:

Thrombocytopenia is a relatively frequent complication of HIV, andis particularly prevalent among hazardous alcohol users (HAU). These findings suggest that TCP is associated with altered levels of BDNF and serotonin, suggesting that they may be the bridge linking TCP and poor viro-immune responses observed in this group. These results could have important clinical and therapeutic implications.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Estados Unidos